transforming growth factor-beta1, hepatitis B virus core protein, recombinant protein, liver fibrosis https://mc06.manuscriptcentral.com/cjpp-pubs The most immunogenic recombinant HBVc+TGF-β1 peptide (HBVc+C) then served as a vaccine in Sprague-Dawley rats with dimethylnitrosamine-induced chronic liver disease. Hepatic fibrosis was documented by serum hyaluronic acid levels, liver histology and real time polymerase chain reaction for hepatic collagen 1(α1) and alpha-smooth muscle actin mRNA expression. Relative to control rats vaccinated with HBVc alone, recombinant HBVc+C vaccinated animals had significantly lower serum hyaluronic acid levels, less histologic evidence of hepatic fibrosis and reduced expression of collagen type 1(α1) and alpha-smooth muscle actin mRNA in the liver. The results of this proof-of-concept study suggest that active immunization against TGF-β1 is a worthwhile strategy to pursue in efforts to prevent hepatic fibrosis associated with chronic liver disease.
INTRODUCTION
Hepatic fibrosis is a common consequence of chronic, necroinflammatory disease of the liver. Of the various cytokines implicated in the pathogenesis of hepatic fibrosis, transforming growth factor-beta1
(TGF-β1) is thought to be primarily involved and certainly, has been the most extensively studied (Alcolado et al. 1997; Biernacka et al. 2011) . Some of the more compelling findings include; 1) TGF-β1 transgenic mice develop significant hepatic fibrosis whereas normal mice do not (Clouthier et al. 1997; Sanderson et al. 1995) , 2) dominant-negative TGF-beta Type II receptors protect against the fibrosis induced by hepatotoxicity (Qi et al. 1999) , 3) soluble Type II receptors inhibit hepatic stem cell (HSC) activation (George et al. 1999 ) and attenuate hepatic fibrosis induced by carbon tetrachloride (CCl4) (Yata et al. 2002) , and 4) daily injections of a peptide -Leu-Ser-Lys-Leu (LSKL) -which represents the specific amino acid sequences at the amino terminus of latency-associated peptide, inhibits TGF-β1 activation and prevents hepatic fibrosis in vivo (Kondou et al. 2003) .
TGF-β1 acts by binding to TGF-β type II receptors present on the surface of HSCs resulting in the aggregation and formation of Type I-II receptor complexes and phosphorylation of the Type I receptor at GS domains (Derynck 1998 ). Activated Type I receptors then phosphorylate Smad 2/3 molecules which associate with Smad 4 to initiate the transcription of genes responsible for HSC proliferation and transformation into myofibroblasts and ultimately, collagen formation (Dooley et al. 2001) .
From a clinical perspective, efforts have focused on interfering with TGF-β1 mediated signaling. These efforts have included the use of angiotensin converting enzyme (ACE) inhibitors, ACE receptor blockers, beta adrenergic blockers and more direct approaches such as infusions of soluble TGF-β receptors and passively administering antibodies to TGF-β1 (Choi et al. 2007; Karimian et al. 2008; Kondou et al. 2003; Strack et al. 2011; Tox and Steffen 2006; Wei et al. 2004 ). To our knowledge, there D r a f t 4 have been no previous attempts to determine whether active immunization against TGF-β1 peptides prevents or attenuates hepatic fibrogenesis in the setting of chronic liver disease. HBVc+B, and 5) adjuvant plus recombinant HBVc+C. Immunization of mice was performed as per our previous publication (Ma et al. 2007) . All mice were immunized subcutaneously with 100µg of recombinant protein. Two weeks after the first injection, a 50µg boost was administered. Mice were sacrificed after an additional two weeks by exsanguination. Serum was collected and stored at -80 0 C until used for subsequent determinations.
MATERIALS AND METHODS

Construction
D r a f t
Enzyme-linked immunosorbent assay (ELISA): An indirect ELISA was employed to screen or identify the antigenic activity of recombinant HBVc-TGF-β1 fragments (HBVc+A, HBVc+B, HBVc+C or TGF-β1) in immunized mice as described previously (Ma et al. 2007) . Polystyrene 96-well plates were coated with 100µl recombinant proteins (4µg/ml) or 100µl recombinant TGF-β1 (1ng/ml from R&D System) in 0.05M carbonate buffer (pH 9.6) and incubated overnight at 4 0 C. After blocking and washing, different dilutions of mouse sera were added and incubated at 4 0 C overnight. Wells were washed and 0.1ml of enzyme-conjugated goat anti-mouse IgG (Sigma, MO, USA) (1:1000 diluted in PBS-T supplemented with 0.2% BSA) was added and incubated for 1 hour at 37 0 C. Color reaction was developed by adding 0.1ml of enzyme substrate (1mg/ml P-nitrophenylphosphate in 0.2M Tris buffer, pH 9.8, Sigma Fast pnitrophenylphosphate tablets) and incubating at room temperature for 1 hour. Absorbance at 405nm was read using a THERMOmax microplate reader (Molecular Devices, CA). Negative controls included coated wells with no mouse serum or no goat anti-mouse IgG in PBS-T with 0.2% BSA. The positive control was a polyclonal antibody against TGF-β1 from R&D System (Minneapolis, MN).
Cellular membrane receptor binding assay:
The Mink lung epithelial cell line (CCL64) was selected for cellular membrane receptor binding assays because of the high density of TGF-β1 receptors presented on its cell membrane (Kramer et al. 1991) . These cells were purchased from ATCC and cultured in DMEM with 5% FBS. Mouse IgG was isolated from mouse serum by incubating 1 ml of mouse serum with 2ml protein A/G solution (Sigma, MO, USA) at 4 0 C for 1 hour and washed three times with PBS (pH 7.4). IgG was then eluted from protein A/G by incubating with 0.2M Glycine pH 3.0 twice and neutralized with 1M Tris-HCl pH 8.0. Membrane receptor binding assays were performed as described previously (Gong et al. 1991 
1992).
Cell proliferation assay: The effects of TGF-β1 and mouse IgG on CCL64 cell proliferation were determined by the WST-1 cell proliferation reagent as described previously (Shen et al. 2003b) . Briefly Reverse-transcriptase polymerase chain reaction: Total RNA was isolated by Trizol reagent as per the manufacturer's instructions for liver tissue. The first strand cDNA synthesis and regular PCR were performed as described previously (Shen et al. 2003a ). The specific primers for rat collagen type 1(α1), α-SMA and TGF-β1 were designed by the Oligo 5.1 program on a Macintosh computer. The primers and PCR conditions are listed in Table 2 . PCR amplification was carried out by applying 30 cycles comprising: denaturation at 94ºC for 1 minute, annealing at different temperatures as in Table 2 
RESULTS
The specificity of recombinant HBVc+C vaccine was demonstrated in Figure 1D ).
The results of serum antibody to TGF-β1 levels in saline and DMN treated rats with and without HBVc and recombinant HBVc+C vaccinations are provided in Figure 2 . Significant antibody levels were only detected in rats treated with DMN and recombinant HBVc+C (p<0.05). In this group anti-TGF-β1 levels were more than twice those of HBVc vaccinated controls and triple those of DMN alone controls.
In terms of necroinflammatory activity and fibrogenesis, compared to healthy controls, serum ALT, TGF-β1 and HA levels were elevated after 4 weeks in all DMN treated groups but in the case of ALT D r a f t 9 and HA levels the extent of the increase in rHBVc+C immunized rats was significantly less than in DMN alone treated controls ( Figure 3A ).
Liver histology was also investigated in these groups ( Figure 3B ). There was significant necroinflammatory disease and fibrosis present in rats treated with DMN alone or DMN plus HBVc vaccination. However, in rats treated with DMN plus recombinant HBVc+C vaccination, both inflammation and fibrosis were attenuated ( Figure 3B and 3C) . Indeed, Masson staining in HBVc+C immunized rat livers were more in keeping with healthy control rats that did not receive DMN.
Immunohistochemical staining for α-SMA and TGF-β1 in the liver revealed significant increases in α-SMA and TGF-β1 staining in DMN alone and DMN plus HBVc treated rats compared to rats treated with DMN plus recombinant HBVc+C (Figure 4 ). However, once again, the extent of α-SMA and TGF-β1 expression in DMN plus recombinant HBVc+C treated rats was less than that of DMN alone treated rats and more in keeping with healthy control rat livers. No deaths occurred in any of the study groups.
DISCUSSION
Vaccine-based approaches are being considered more frequently for the treatment of various noninfectious disorders, particularly cancers. For example, peptides of xenogeneic vascular endothelial growth factor (VEGF) have been shown to induce the production of VEGF-specific auto-antibodies and D r a f t thereby, inhibit cancer cell proliferation and tumor progression in animal models of cancer (Wei et al. 2000) . In other studies, vaccination with chicken homologous matrix metalloproteinase-2, induced antibodies that exhibit marked anti-tumor properties (Su et al. 2003) . To our knowledge, this is unique attempt to employ a vaccine-based approach to the treatment of hepatic fibrosis.
TGF-β1 plays a pivotal role in liver fibrosis and has been proposed as a surrogate marker. Serum TGF-β1 could be used to assess therapeutic outcome and short-term prognosis of HCV-related chronic hepatitis (Tarantino et al. 2008b) . Suppressing the over-expression of TGF-β1 or blocking its signaling pathway has been considered as a promising therapeutic strategy for liver fibrosis. For example, Two TGF-beta1 kinoid vaccines prepared by cross-linking TGF-beta1-derived polypeptides (TGF-β1 (25) We employed the hepatitis B virus core as our carrier protein because it has been demonstrated to form self-assembled particles when expressed in E. coli cells (Stahl et al. 1982) . These stable particles can be easily purified and are highly immunogenic in laboratory animals (Cohen and Richmond 1982) . Nonethe-less, although we constructed three recombinant constructs of HBVc, only recombinant HBVc+C formed self-assembled particles. Why the others did not is unclear, however, it has been reported that the length of insertion and certain amino acids (arginine rich C-terminals) can alter the ability to form D r a f t 11 self-assembled particles (Koletzki et al. 1997; Ulrich et al. 1992 ). In our study, the length of peptides should not have been an issue because all peptides were similar in length (between 9 and 12 amino acids). Thus, the composition of the amino acids may serve as a more likely explanation for this finding.
It is important to note that although recombinant HBVc+C vaccination resulted in a significant increase in antibody against TGF-β1, serum TGF-β1 protein and hepatic TGF-β1 mRNA levels remained similar to those of the appropriate controls. Moreover, although hepatic TGF-β1 mRNA levels remained unaltered, hepatic TGF-β1 protein was reduced by vaccination with recombinant HBVc+C. These observations raise the question as to whether vaccination with small TGF-β1 peptide will contribute to a widespread disruption of cytokine homeostasis or whether the effect will be restricted to sites of tissue injury. Relevant to this issue is the belief that cytokine expression is largely regulated by local autocrine and paracrine activities. Indeed, previous studies have demonstrated that increases in TGF-β1 and TGF-β1 receptor expression tend to be limited to sites of injury (Munger et al. 1999 ). In addition, only significant disruptions in tissue integrity allow large, circulating molecules such as IgG, access to the cell surfaces of injured tissues. Accordingly, it is conceivable that the effects of antibodies derived from recombinant HBVc+C vaccination may be relatively restricted to the site of injury. None-the-less, additional studies are required to address this important issue.
A somewhat surprising finding in our study was the limited inflammatory cell infiltrate in the livers of DMN-treated rats vaccinated with recombinant HBVc+C despite an elevation in serum ALT levels.
While the explanation for this finding remains unclear, TGF-β1 regulation of macrophage migration could explain why DMN-induced hepatocyte necrosis would remain unaffected while inflammatory cell migration is inhibited (Kim et al. 2006) . Moreover, apoptotic cell death could be another reason because it is caspase-dependent and associated with mitochondrial membrane depolarization and cytochrome c release (Tarantino et al. 2011) .
There are a number of limitations to this study that warrant emphasis. First, immunizations and DMN treatments were initiated simultaneously. Thus, it remains to be determined whether the vaccination strategy is of value in the setting of established fibrosis or cirrhosis. Second, the duration of vaccine efficacy needs to be determined in long-term studies. Third, although DMN-induced liver injury is a well-established model of chronic liver disease, studies employing other models in other animal species are still warranted. Fourth, with respect to future clinical applications, it must be noted that the immunogenicity of vaccines is suboptimal in the setting of advanced liver disease and in subjects receiving immunosuppressive regimens (Cheong et al. 2006; Kumar et al. 2011 ). Also to be determined is whether the recombinant HBVc+C vaccine would be immunogenic in individuals with chronic HBV infections or antibodies to HBV core particles. Finally, no attempt was made to induce injury or inflammation outside the liver to determine whether "beneficial" wound healing would be impaired in TGF-β1 vaccinated subjects, or to examine whether this recombinant vaccine are effective in attenuating development of liver fibrosis in non-alcoholic fatty liver disease, which has been shown enhanced serum concentration of TGF-β1 (Tarantino et al. 2008a ).
In conclusion, in this proof-of-concept study we have constructed a recombinant HBVc+TGF-β1 peptide vaccine which generates antibodies against TGF-β that inhibit TGF-β1 binding and biological activities in vitro and the development of hepatic fibrosis in vivo. Further studies are required to determine whether this strategy has a role to play in the treatment of patients with chronic liver disease. Ulrich, R., Borisova, G.P., Gren, E., Berzin, I., Pumpen, P., Eckert, R., Ose, V., Siakkou, H., Gren, E.J., 
